Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Essilor: 2017 Registration Document Filed

Essilor International
Posted on: 28 Mar 18

  2017 Registration Document Filed

PDF Version of the news release

Charenton-le-Pont, France (March 28, 2018 - 6:00 pm CET) - The 2017 Essilor Registration Document was filed in French version with the Autorité des Marchés Financiers (AMF) on March 27, 2018.

The Registration Document includes:

  1. The Annual Financial Report, with:
    • The parent company financial statements;
    • The consolidated financial statements;
    • The management report in compliance with article L.225-100 of the French Commercial Code;
    • A statement by the persons responsible for the Registration Document;
    • The report of the Auditors on the parent company and consolidated financial statements;
    • Information concerning Auditors' fees.
  2. The report on corporate governance as per the article L.225-37 of the French Commercial Code.

From now on, the French version is available to the public free of charge, as provided for in applicable legislation, and may be downloaded from Essilor's corporate website www.essilor.com .
The English version will be available on the website on April 3, 2018 at the latest.

About Essilor
Essilor International (Compagnie Générale d'Optique) ("Essilor") is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux ® , Crizal ® , Transitions ® , Eyezen TM , Xperio ® , Foster Grant ® , Bolon TM and Costa ® . It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of around €7.5 billion in 2017 and employs approximately 67,000 people worldwide. It markets its products in more than 100 countries and has 34 plants, 481 prescription laboratories and edging facilities, as well as 4 research and development centers around the world. For more information, please visit www.essilor.com .
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. 
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

------------------------

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16

PDF Version of the news release


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Essilor International via GlobeNewswire
HUG#2180232
GlobeNewswire
globenewswire.com

Last updated on: 29/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.